World Investment Advisors Buys 1,444 Shares of Cencora, Inc. (NYSE:COR)

World Investment Advisors boosted its position in Cencora, Inc. (NYSE:COR - Free Report) by 7.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,761 shares of the company's stock after purchasing an additional 1,444 shares during the quarter. World Investment Advisors' holdings in Cencora were worth $5,773,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Hoey Investments Inc. bought a new stake in Cencora in the 1st quarter valued at $28,000. Banque Transatlantique SA acquired a new position in Cencora in the 4th quarter valued at $29,000. SBI Securities Co. Ltd. acquired a new position in Cencora in the 4th quarter valued at $30,000. Vermillion Wealth Management Inc. acquired a new position in Cencora in the 4th quarter valued at $38,000. Finally, Golden State Wealth Management LLC raised its holdings in Cencora by 157.6% in the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after acquiring an additional 104 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 0.9%

Shares of NYSE:COR traded up $2.74 during midday trading on Monday, reaching $298.97. The company's stock had a trading volume of 322,452 shares, compared to its average volume of 1,652,687. The firm has a market capitalization of $57.95 billion, a price-to-earnings ratio of 34.68, a PEG ratio of 1.47 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The firm has a 50 day moving average price of $291.12 and a two-hundred day moving average price of $267.80. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the business earned $3.80 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Analysts Set New Price Targets

Several brokerages have weighed in on COR. Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a report on Monday, June 30th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Robert W. Baird lifted their price target on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Citigroup lifted their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $306.33.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares of the company's stock, valued at $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,127 shares of company stock worth $9,812,296. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.